ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
— Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients…
Good Purpose Investments Engages MCS Market Communication Services for Online Marketing Services
DelphX Closes Non-Brokered Unit Private Placement
Google Rank Tracker Without a Subscription: SpeedyIndex Launches Pay-Per-Check Rank Tracker with API
Frontline Source Group Launches Fractional Executive Division
Eguana Announces Completion of Second and Final Tranche and Closing of Previously Announced Convertible Debenture Financing